Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
Reena P Thomas, Lawrence Recht, Seema NagpalDepartment of Neurological Sciences, Stanford University Hospital, Stanford, CA, USAAbstract: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy a...
Guardado en:
Autores principales: | Thomas RP, Recht L, Nagpal S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9b57b4faeae04177967a9e17ae0e410b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
por: Eskander RN, et al.
Publicado: (2013) -
The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway
por: Ming Ji, et al.
Publicado: (2021) -
Advances in the use of topical imiquimod to treat dermatologic disorders
por: Francesco Lacarrubba, et al.
Publicado: (2008) -
Retraction notice to 'Physcion 8-O-β-glucopyranosideregulates cell cycle, apoptosis, and invasion in glioblastoma cells through modulating Skp2' [Biomed. Pharmacother. 95 (2017) 1129–1138]
por: Wen Li, et al.
Publicado: (2021) -
Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda M, et al.
Publicado: (2015)